title: Securin promotes the identification of favourable outcome in invasive breast cancer.
abstract: BACKGROUND
  Securin is a recently recognised oncogene with multiple known functions in initiation, progression and cell cycle regulation in several malignant diseases, including breast carcinoma.
  
  
  METHODS
  In this paper, the prognostic value of securin is evaluated by immunohistochemistry in 310 patients diagnosed with invasive breast cancer during a mammographic screening programme in Central Finland. All patients were directed to modern surgical and oncological treatments and were followed up for a maximum of 20 years.
  
  
  RESULTS
  Our results suggest that securin immunopositivity is an independent prognosticator of invasive breast cancer. In our study, securin predicted breast cancer-specific survival among all cases of invasive breast cancer and subgroups divided according to histological type, Ki-67 proliferation status and tumour size. Especially in a multivariate analysis standardised for axillary lymph node status, patient's age and tumour size at the time of diagnosis, securin immunopositivity indicated a 13.1-fold risk of breast cancer death (P=0.024) among invasive ductal breast carcinomas with low Ki-67 positivity.
  
  
  CONCLUSIONS
  Our present and previous results suggest that securin could be useful in clinical pathology to intensify the power of the established prognosticators of invasive breast cancer and, especially, to assist in identifying patients with a more favourable outcome than that indicated by Ki-67 alone.
authors.affiliation: Department of Pathology, University of Turku, Kiinamyllynkatu 10, Turku FIN-20520, Finland. kattal@utu.fi
authors.forename: K
authors.initials: K
authors.lastname: Talvinen
authors.forename: H
authors.initials: H
authors.lastname: Karra
authors.forename: S
authors.initials: S
authors.lastname: Hurme
authors.forename: M
authors.initials: M
authors.lastname: Nykänen
authors.forename: A
authors.initials: A
authors.lastname: Nieminen
authors.forename: J
authors.initials: J
authors.lastname: Anttinen
authors.forename: T
authors.initials: T
authors.lastname: Kuopio
authors.forename: P
authors.initials: P
authors.lastname: Kronqvist
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D064249:Securin
chemical_list: D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D064249:Securin; C578002:pituitary tumor-transforming protein 1, human
references.citation: J Clin Endocrinol Metab. 2005 Jun;90(6):3715-23
references.pmid: 15769981
references.citation: Br J Cancer. 2008 Jul 22;99(2):335-40
references.pmid: 18594525
references.citation: Cell. 2005 Mar 25;120(6):739-46
references.pmid: 15797376
references.citation: Clin Med Res. 2006 Jun;4(2):130-7
references.pmid: 16809406
references.citation: Am J Pathol. 2001 Apr;158(4):1245-51
references.pmid: 11290542
references.citation: Am J Clin Pathol. 1998 Jul;110(1):24-31
references.pmid: 9661919
references.citation: Anticancer Res. 2006 Mar-Apr;26(2A):1253-9
references.pmid: 16619532
references.citation: Oncogene. 1999 Sep 23;18(39):5473-6
references.pmid: 10498901
references.citation: Br J Cancer. 1989 Jun;59(6):943-7
references.pmid: 2472168
references.citation: Histopathology. 2008 Dec;53(6):642-9
references.pmid: 19076680
references.citation: J Pathol. 1999 Nov;189(3):309-18
references.pmid: 10547591
references.citation: Mol Endocrinol. 2000 Aug;14(8):1137-46
references.pmid: 10935539
references.citation: Pathobiology. 2008;75(2):95-103
references.pmid: 18544964
references.citation: J Surg Res. 2005 Nov;129(1):142-6
references.pmid: 15936773
references.citation: Nat Genet. 2003 Jan;33(1):49-54
references.pmid: 12469122
references.citation: Nat Med. 1998 Jul;4(7):844-7
references.pmid: 9662379
references.citation: J Natl Cancer Inst. 1999 Feb 3;91(3):271-8
references.pmid: 10037106
references.citation: Curr Biol. 2002 Aug 20;12(16):1368-78
references.pmid: 12194817
references.citation: Nat Rev Cancer. 2005 Oct;5(10):773-85
references.pmid: 16195750
references.citation: Oncol Rep. 2006 Jun;15(6):1569-74
references.pmid: 16685397
references.citation: J Pathol. 2000 Dec;192(4):549-53
references.pmid: 11113875
references.citation: J Clin Endocrinol Metab. 2003 May;88(5):2341-7
references.pmid: 12727994
references.citation: Hum Pathol. 1995 Oct;26(10):1086-92
references.pmid: 7557941
references.citation: Cancer Res. 2008 May 1;68(9):3214-24
references.pmid: 18451147
references.citation: World J Gastroenterol. 2005 Jun 7;11(21):3245-9
references.pmid: 15929175
references.citation: J Mol Endocrinol. 2009 Feb;42(2):87-103
references.pmid: 18984771
references.citation: Blood. 2003 Jan 15;101(2):681-9
references.pmid: 12393683
references.citation: Breast Cancer Res. 2008;10(2):R26
references.pmid: 18371194
references.citation: Clin Endocrinol (Oxf). 2006 Oct;65(4):536-43
references.pmid: 16984249
references.citation: J Exp Med. 1981 Dec 1;154(6):1899-909
references.pmid: 6172535
references.citation: J Cell Biol. 2002 Jun 24;157(7):1125-37
references.pmid: 12070128
references.citation: Cell. 1998 Jun 12;93(6):1067-76
references.pmid: 9635435
references.citation: Mod Pathol. 2009 Feb;22(2):273-81
references.pmid: 18997736
references.citation: Breast Cancer Res Treat. 2009 May;115(2):241-54
references.pmid: 18665447
references.citation: Oncogene. 2004 Mar 15;23(11):2016-27
references.pmid: 15021889
references.citation: Cancer. 1993 Jun 15;71(12):3926-31
references.pmid: 8508358
references.citation: Jpn J Clin Oncol. 2002 Jul;32(7):233-7
references.pmid: 12324572
references.citation: Mol Cancer Ther. 2005 Apr;4(4):562-8
references.pmid: 15827329
references.citation: Oncogene. 1998 Oct 29;17(17):2187-93
references.pmid: 9811450
references.citation: Histopathology. 1991 Nov;19(5):403-10
references.pmid: 1757079
references.citation: Pathology. 2009 Jan;41(1):77-88
references.pmid: 19089743
references.citation: Hum Pathol. 2001 Mar;32(3):311-9
references.pmid: 11274641
references.citation: Anal Cell Pathol. 1989 Feb;1(1):25-39
references.pmid: 2488698
references.citation: Endocr Relat Cancer. 2008 Sep;15(3):721-43
references.pmid: 18753362
references.citation: J Clin Invest. 2002 Jan;109(2):277-83
references.pmid: 11805140
references.citation: Blood. 1997 Jul 1;90(1):226-33
references.pmid: 9207457
references.citation: World J Gastroenterol. 2004 Feb 15;10(4):481-3
references.pmid: 14966902
references.citation: Mod Pathol. 2005 Jul;18(7):985-90
references.pmid: 15846392
references.citation: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references.pmid: 12490681
references.citation: Mol Pharmacol. 2006 Jan;69(1):154-64
references.pmid: 16219911
references.citation: Histol Histopathol. 2007 Feb;22(2):219-26
references.pmid: 17149695
references.citation: Breast. 2004 Feb;13(1):80-1
references.pmid: 14759723
references.citation: Breast. 2008 Aug;17(4):323-34
references.pmid: 18455396
references.citation: Endocr Rev. 2007 Apr;28(2):165-86
references.pmid: 17325339